![Michael Austwick](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Austwick
No open positions remaining
Profile
Michael Austwick formerly worked at Vectura Group Ltd., as Chief Executive Officer from 2022 to 2023, Verona Pharma Plc, as Independent Non-Executive Director from 2024 to 2025, AstraZeneca, Inc., as Vice President-Global Inhaled Respiratory, and Novartis, Inc., as Head-Global Respiratory Franchise.
Mr. Austwick received his graduate degree from The University of Hull and undergraduate degree from City University London.
Former positions of Michael Austwick
| Companies | Position | End |
|---|---|---|
| VERONA PHARMA PLC | Director/Board Member | 2025-10-06 |
| VECTURA GROUP | Chief Executive Officer | 2023-10-31 |
AstraZeneca, Inc.
 AstraZeneca, Inc. BiotechnologyHealth Technology Manufactures vaccines | Corporate Officer/Principal | - |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco, CA. | Corporate Officer/Principal | - |
Training of Michael Austwick
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
8
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco, CA. | Health Technology |
Vectura Group Ltd.
 Vectura Group Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures inhalation drugs and medical devices | Health Technology |
The University of Hull
 The University of Hull Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Verona Pharma Plc
 Verona Pharma Plc Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of allergic rhinitis and other chronic respiratory diseases | Health Technology |
AstraZeneca, Inc.
AstraZeneca, Inc. BiotechnologyHealth Technology Manufactures vaccines | Health Technology |
City University London
 City University London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Michael Austwick
